Stockholm, November 17, 2025 – Purpose Pharma International AB today announced that ATTROGY® (diflunisal) is now available in Germany for the treatment of hereditary transthyretin-mediated (hATTR or ATTRv) amyloidosis in adult patients

Stockholm, July 31, 2025 – Purpose Pharma International AB today announced that the European Commission (EC) has granted ATTROGY® (diflunisal) marketing authorization for the treatment of hereditary transthyretin-mediated (hATTR or

Stockholm, April 28, 2025 – Purpose Pharma International AB today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a

Purpose Pharma International AB is pleased to announce that Eir Ventures has invested in an extension of the Series A financing completed in 2023.

Industrifonden has made a strategic investment in Purpose Pharma International AB, a pharmaceutical company focusing on specialty products for rare diseases for patient groups with limited alternatives.